For the Inventor, By the Inventor

Enter assignee name

Gunma University

USPTO Granted Patents = 114

% Expired Patents = 36.8

CIPO Patents = 4

EPO Patents = 59

Forward Citations = 203

Loading Chart...

Loading Chart...

286 inventors (with patents filed for the assignee):

Jun-ichi Ozaki (16 out of 19 patents)

Takeaki Kishimoto (9 out of 28 patents)

Masayasu Kuwahara (9 out of 9 patents)

4. Rieko Kobayashi (6 out of 6 patents)

5. Yasuo Imashiro (6 out of 60 patents)

6. Iwao Waga (5 out of 29 patents)

7. Jou Akitomi (5 out of 25 patents)

8. Hirotaka Minagawa (5 out of 12 patents)

9. Katsunori Horii (5 out of 20 patents)

10. Naoto Kaneko (5 out of 18 patents)

11. Hiroki Uehara (5 out of 5 patents)

12. Takeshi Yamanobe (5 out of 5 patents)

13. Takuya Maie (4 out of 4 patents)

14. Soshi Shiraishi (4 out of 4 patents)

15. Hiroyuki Takeno (4 out of 4 patents)

Core Competencies:

Oxygen Concentration

Fluorescence Imaging

Gene Expression

Anti-PD-1 Therapy

Cancer Therapeutics

Nucleoside Derivatives

Hydrogel Composition

Carbon Catalysts

Electrolytic Solutions

Lithium-Ion Batteries

Volumetric Display

Ultrasonic Imaging

114 patents: Sort by Forward Citations

1. 12736536 - Cancer biomarker in pancreatic cancer or malignant intraductal papillary mucinous neoplasm (2026-09-15),

2. 12454541 - Reagent for measuring oxygen concentration in cell and tissue (2025-10-28),

3. 12442017 - Microglial selective gene expression vector (2025-10-14),

4. 12306194 - Reagent for fluorescence imaging of lipid droplets in cell and tissue (2025-05-20),

5. 12144619 - Blood measurement device (2024-11-19),

6. 12123106 - Biopolymer concentration method, crystallization method, and nanostructured substrate (2024-10-22),

7. 11899019 - Method for predicting efficacy of anti-PD-1 antibody or anti-PD-L1 antibody therapy, method for evaluating cancer grade, and method for enhancing efficacy of anti-PD-1 antibody or anti-PD-L1 antibody therapy (2024-02-13),

8. 11858984 - Anti-S100A8/A9 antibody and use thereof (2024-01-02),

9. 11678077 - Imaging device (2023-06-13),

10. 11668952 - Volumetric display (2023-06-06),

11. 11643660 - Nucleoside derivative or salt thereof, polynucleotide synthesis reagent, method for producing polynucleotide, polynucleotide, and method for producing binding nucleic acid molecule (2023-05-09),

12. 11643430 - Porphyrin compound or salt thereof, cancer therapeutic agent, photosensitizer, and fluorescent probe (2023-05-09),

13. 11591623 - DNA methylation editing kit and DNA methylation editing method (2023-02-28),

14. 11559602 - Sol for tissue perforation closure, ulcer protection, and vascular embolization (2023-01-24),

15. 11499138 - Method for manufacturing peripheral nerve cells (2022-11-15),

Company Overview

Gunma University, located in Japan, is a prominent institution specializing in biotechnology innovations. The university focuses on advancing research in various fields, including oxygen concentration technologies, fluorescence imaging techniques, and gene expression studies. Its work extends to developing therapies for cancer, particularly through anti-PD-1 strategies, and exploring nucleoside derivatives. Additionally, Gunma University is engaged in the creation of hydrogel compositions and carbon catalysts, contributing significantly to the scientific community and healthcare advancements.

Profile summary synthesized from public USPTO records and patent filings.

Company Badge

USPTO Data Jan 1 1976 - Oct 13 2026

114 Patents

#3 in Gunma

#1,040 in Japan

#6,944 in the World

Gunma University

Forward Citations = 203

286 inventors:

Jun-ichi Ozaki (16 out of 19 patents)

Takeaki Kishimoto (9 out of 28 patents)

Masayasu Kuwahara (9 out of 9 patents)

4. Rieko Kobayashi (6 out of 6 patents)

5. Yasuo Imashiro (6 out of 60 patents)

IDiyas Innovation Intelligence. (2026). Company Patent Portfolio: Gunma University. Retrieved from https://idiyas.com/company/gunma-university

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]

Loading…